All Stories

  1. Evaluation of the functional impact of rare CYP2C19 missense variants identified in understudied Populations: An Integrated in silico and in vitro analysis
  2. Pharmacogenomic biomarkers of ACE inhibitor–induced cough in a multi-ethnic UAE cohort
  3. A multi-centre observational cohort study on pharmacogenomic predictors of rosuvastatin discontinuation in a multiethnic population
  4. Knowledge and Views of Patients With Cardiovascular Disease Toward Pharmacogenomics in The United Arab Emirates
  5. Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE’s multiethnic population
  6. Revisiting Chromosomal Translocations: Insights From Healthy Individuals and Lymphoma
  7. Challenges in improving genomic literacy, knowledge, and awareness
  8. Contributors
  9. Comparative Analysis of Atorvastatin and Rosuvastatin Side Events and Risk Factors in the UAE Multiethnic Population: Focus on Pharmacogenomic Variants
  10. Meta-analysis of genomic variants in power and endurance sports to decode the impact of genomics on athletic performance and success
  11. Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population
  12. Safety Pharmacology in the Era of Precision Medicine
  13. Safety Pharmacology in the Era of Precision Medicine
  14. Antihypertensives associated adverse events: a review of mechanisms and pharmacogenomic biomarkers available evidence in multi-ethnic populations
  15. The Utility of CYP2D6 and CYP2C19 Variants to Guide Pharmacological Treatment in Complex Unipolar Major Depression: A Pilot Longitudinal Study
  16. Pharmacogenomics at the post-pandemic: If not now, then when?
  17. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates
  18. Mendelian randomization in pharmacogenomics: The unforeseen potentials
  19. Long-Term Effects of Pediatric Acute Lymphoblastic Leukemia Chemotherapy: Can Recent Findings Inform Old Strategies?
  20. Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide
  21. Current opinion on the pharmacogenomics of paclitaxel-induced toxicity
  22. Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm)
  23. Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations
  24. Association of variants inPTPN22,CTLA‐4,IL2‐RA, andINSgenes with type 1 diabetes in Emiratis
  25. Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy
  26. VKORC1 variants as significant predictors of warfarin dose in Emiratis
  27. Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations
  28. Genotype–phenotype spectrum of PYCR1-related autosomal recessive cutis laxa
  29. High prevalence of genetic abnormalities in Middle Eastern patients with idiopathic non-obstructive azoospermia
  30. GJB2 gene mutations in Syrians with sensorineural hearing loss
  31. A review of 1125 cases referred for cytogenetic analysis in Syria